For the quarter ended September 2024, Supernus Prescription drugs (SUPN) reported income of $175.69 million, up 14.2% over the identical interval final 12 months. EPS got here in at $1.06, in comparison with -$0.29 within the year-ago quarter.
The reported income compares to the Zacks Consensus Estimate of $155.06 million, representing a shock of +13.30%. The corporate delivered an EPS shock of +171.79%, with the consensus EPS estimate being $0.39.
Whereas buyers intently watch year-over-year adjustments in headline numbers — income and earnings — and the way they evaluate to Wall Road expectations to find out their subsequent plan of action, some key metrics all the time present a greater perception into an organization’s underlying efficiency.
As these metrics affect top- and bottom-line efficiency, evaluating them to the year-ago numbers and what analysts estimated helps buyers undertaking a inventory’s worth efficiency extra precisely.
Right here is how Supernus carried out within the simply reported quarter when it comes to the metrics most generally monitored and projected by Wall Road analysts:
- Revenues- Web product sales- Trokendi XR: $15.30 million in comparison with the $10.50 million common estimate primarily based on three analysts. The reported quantity represents a change of -25.7% 12 months over 12 months.
- Revenues- Web product sales- Oxtellar XR: $29.80 million in comparison with the $19.57 million common estimate primarily based on three analysts. The reported quantity represents a change of +0.7% 12 months over 12 months.
- Revenues- Web product sales- Qelbree: $62.40 million versus the three-analyst common estimate of $60.01 million. The reported quantity represents a year-over-year change of +68.2%.
- Revenues- Web product gross sales: $170.30 million versus $149.66 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +14.3% change.
- Revenues- Royalty revenues: $5.39 million versus $5.93 million estimated by three analysts on common. In comparison with the year-ago quarter, this quantity represents a +9.9% change.
- Revenues- Web product sales- GOCOVRI: $35.60 million in comparison with the $34.36 million common estimate primarily based on three analysts. The reported quantity represents a change of +8.2% 12 months over 12 months.
- Revenues- Web product sales- Different: $7.30 million versus $7.77 million estimated by two analysts on common. In comparison with the year-ago quarter, this quantity represents a 0% change.
- Revenues- Web product sales- APOKYN: $19.90 million versus the two-analyst common estimate of $16.25 million. The reported quantity represents a year-over-year change of -7.4%.
View all Key Company Metrics for Supernus here>>>
Shares of Supernus have returned +6.1% over the previous month versus the Zacks S&P 500 composite’s +0.4% change. The inventory presently has a Zacks Rank #4 (Promote), indicating that it might underperform the broader market within the close to time period.
Analysis Chief Names “Single Finest Choose to Double”
From hundreds of shares, 5 Zacks specialists every have chosen their favourite to skyrocket +100% or extra in months to come back. From these 5, Director of Analysis Sheraz Mian hand-picks one to have essentially the most explosive upside of all.
This firm targets millennial and Gen Z audiences, producing practically $1 billion in income final quarter alone. A latest pullback makes now a great time to leap aboard. After all, all our elite picks aren’t winners however this one might far surpass earlier Zacks’ Shares Set to Double like Nano-X Imaging which shot up +129.6% in little greater than 9 months.
Free: See Our Top Stock And 4 Runners Up
Supernus Pharmaceuticals, Inc. (SUPN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the writer and don’t essentially mirror these of Nasdaq, Inc.
